Indeed, treatment induced a specific decrease in the number of activated Tregs (CD4+/Foxp3+/CTLA4+) in the tumor microenvironment, without modulating Ki67 and HLA-DR activation markers. The gene discussed is MKI67; the disease is neoplasm.